Target type: biologicalprocess
The invasion by a symbiont of a cell of a host organism, forming a vacuole in which the symbiont resides. The vacuole membrane is formed from lipids and proteins derived from both host and symbiont. Begins when the symbiont attaches on to the host cell membrane which invaginates and deepens as the symbiont enters, and ends when the host cell membrane closes behind the newly-formed vacuole. [GOC:jl, PMID:18665841, PMID:8690024, PMID:9580555]
The entry of a symbiont-containing vacuole into a host cell is a complex and tightly regulated process that varies depending on the specific symbiosis. However, some general steps are common:
1. **Attachment:** The symbiont-containing vacuole first attaches to the host cell membrane. This attachment can be mediated by specific receptors on the host cell surface and ligands on the vacuole.
2. **Internalization:** Once attached, the vacuole is internalized into the host cell through a process called endocytosis. This process involves the invagination of the host cell membrane, surrounding the vacuole, and eventually pinching off to form a vesicle containing the vacuole.
3. **Trafficking:** The newly formed vesicle containing the symbiont-containing vacuole is transported through the host cell cytoplasm to its final destination. This trafficking often involves specific motor proteins that move along cytoskeletal filaments, allowing the vesicle to travel to the appropriate location.
4. **Fusion:** Once at its destination, the vacuole membrane can fuse with the host cell membrane, releasing the symbiont into the host cell cytoplasm. This fusion can be regulated by specific fusion proteins on both the vacuole and host cell membranes.
5. **Establishment of the Symbiotic Relationship:** Once inside the host cell, the symbiont can establish a symbiotic relationship with the host cell. This can involve various interactions, such as the exchange of nutrients and signaling molecules.
It is important to note that the specific mechanisms of entry, trafficking, and fusion can vary significantly between different symbioses. For instance, some symbionts may enter the host cell through phagocytosis, while others may enter through a process called microinjection. Additionally, the fate of the symbiont-containing vacuole can vary, with some symbionts remaining within the vacuole, while others escape into the host cell cytoplasm.'
"
Protein | Definition | Taxonomy |
---|---|---|
Integrin alpha-V | An integrin alpha-V that is encoded in the genome of human. [PRO:DNx, UniProtKB:P06756] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1-(3-chlorophenyl)biguanide | 1-(3-chlorophenyl)biguanide: RN given refers to parent cp; a 5-HT3 receptor agonist | biguanides; monochlorobenzenes | |
phenyl biguanide | phenyl biguanide : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a phenyl group. phenyl biguanide: RN given refers to parent cpd | guanidines | central nervous system drug |
4-chlorophenylbiguanide | |||
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
tetraiodothyroacetic acid | 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'. tetraiodothyroacetic acid: RN given refers to parent cpd; structure | 2-halophenol; aromatic ether; iodophenol; monocarboxylic acid | apoptosis inducer; human metabolite; thyroid hormone |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine | |||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
sk&f 107260 | SK&F 107260: structure given in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
elarofiban | elarofiban: a GPIIb and GPIIIa receptor antagonist; structure in first source | ||
eptifibatide | homodetic cyclic peptide; macrocycle; organic disulfide | anticoagulant; platelet aggregation inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
sb 223245 | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
sb 273005 |